As the trilogue negotiations on the Critical Medicines Act (CMA) continue, the BioMed Alliance has published a statement outlining the concerns and recommendations of healthcare professionals across Europe. At this pivotal moment in the legislative process, it is crucial that the voices of the medical community are shared.
The CMA holds the potential to improve the availability, supply, and production of essential medicines across the EU but some measures need to be considered. In our statement, we highlight the need for a strong, coordinated EU approach to address the persistent challenge of medicine shortages. We emphasise several key issues, such as binding supply obligations, transparent procurement rules, and the active involvement of healthcare professionals and patient organisations to ensure the sustainability and accessibility of critical medicines across Member States.
